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Abstract
To evaluate the ability of magnetic resonance imaging (MRI) to predict pathologic complete response (pCR) after neoadjuvant
chemoradiation therapy (CRT) in patients with clinical T1/T2 rectal cancer to indicate candidates for organ-saving strategies.
Between 2012 and 2016, 38 patients with clinical T1/T2 rectal cancer received neoadjuvant CRT. Radiologic complete response
(rCR) was assigned when dense fibrotic tissue without tumor signal intensity was observed on post-CRT MRI. Surgical pathologic
assessment was used to evaluate tumor regression. The association between rCR and the mural extent of the primary tumor, pCR,
and pathologic T stage were analyzed.
In rCR patients, the pCR rate was higher; the odds of achieving pCR were 8.00 times higher than for non-rCR patients (P= .02).
rCR patients were also more likely to have early-stage cancer than non-rCR patients (P=0.01). Patients with partial extent of the
primary tumor on post-CRTMRI weremore likely to be diagnosed with early-stage cancer than those with transmural extent (P= .01).
rCR indicated by post-CRT MRI can be used as a supportive factor to predict pCR after neoadjuvant CRT in patients with clinical
T1/T2 rectal cancer and can guide management decisions around organ-saving treatments.
Abbreviations: 5-FU = 5-fluorouracil, CR = complete response, CRT = chemoradiation therapy, TME = total mesorectal
excision, MRI =magnetic resonance imaging, mrTRG =MRI tumor regression grade, OR = odds ratio, pCR = pathologic complete
response, PPV = positive predictive value, rCR = radiologic complete response.
Keywords: concurrent chemoradiotherapy, MRI, organ preservation, rectal cancer1. Introduction
Total mesorectal excision (TME) is the standard treatment for
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chemoradiation therapy (CRT). After CRT, rectal cancers
demonstrate variable degrees of tumor response, including
pathologic complete response (pCR) in 15% to 27% of
patients.[1] Patients with complete response (CR) or tumor
downstaging after neoadjuvant CRT can achieve excellent local
tumor control and a better quality of life, and organ-preserving
treatments, such as watch-and-wait approach or local excision
can be performed instead of TME.[2,3]
However, local tumor recurrence and compromised patient
survival are major concerns in conducting organ-preserving
treatments instead of radical surgery. A high rate of local tumor
recurrence was observed in patients with T1/T2 rectal cancer
after local excision alone.[4,5] CRT before local excision can
decrease the incidence of local tumor recurrence,[5] and proper
preoperative selection of patients with T1 rectal cancer after CRT
lowers local recurrence.[6] Accordingly, organ preservation
strategies can be adopted in a selected group of patients with
optimal responses to CRT.[7–14]
Unfortunately, the accurate identification and prediction of
pCR or early-stage cancer remains a major challenge.[15]
Surgeons are often reluctant to deviate from TME because of
concerns about viable cancer cells remaining in the rectal wall or
mesorectal lymph nodes, even with clinical CR after CRT.[16]
Therefore, organ-saving treatments should be carefully applied in
only select situations in which clinical CR is conservatively
defined to maximize its positive predictive value (PPV) for pCR.
Magnetic resonance imaging (MRI) is the recommended
imaging tool for preoperative staging and post-treatment
evaluation in patients with rectal cancer.[17,18] After CRT, a
Bae et al. Medicine (2020) 99:42 Medicinesoft tissue tumor is usually replaced by fibrotic tissue, and low
signal intensity on a T2-weighted image is accepted as an
indicator of CRT-induced fibrosis.[19] Comparing low signal
intensity fibrotic tissue to intermediate signal intensity residual
tumors, the MRI and Rectal Cancer European Equivalence
(MERCURY) study group proposed MRI tumor regression
grades (mrTRG) for assessing patients with rectal cancer after
CRT[20] that were later demonstrated to be highly sensitive to
detect pCR.[21]
In this study, we aimed to evaluate the ability of radiologic CR
(rCR) viaMRI, defined as either complete normalization of rectal
wall or fibrotic scar only, to predict pCR or early-stage cancer
after neoadjuvant CRT in patients with clinical T1/T2 rectal
cancer to elucidate the identification of patient candidates for
organ-saving strategies.2. Materials and methods
2.1. Study population
Institutional review board at our institution approved this study,
and the requirement for informed consent was waived. Between
January 2012 and May 2016, we retrospectively registered 696
patients with clinical T1/T2 rectal cancer. Among these patients,
41 met the following inclusion criteria: they1. received neoadjuvant CRT before the surgery and
2. received both baseline and post-CRT MRI.
Neoadjuvant CRT is not standard treatment for clinical T1/T2
rectal cancers, but, in this study, patients received neoadjuvant
CRT due to:1. suspicion of regional or pelvic sidewall lymph nodemetastasis,
2. sphincter preservation.
Since mrTRG is unreliable in the presence of a large mucinous
component and precise cancer staging is difficult when tumorFinal study group: 
n=38
Between Jan 2012 and May 2016
696 patients with clinical T1/T2 rectal ca
Inclusion Criteria:
a) Received neoadjuvant chemoradiatio
b) Performed initial and post-treatment 
n=41
Figure 1. Flow diagram
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perforation has occurred, two patients were excluded. Addition-
ally, one patient was excluded because he received TME 1 year
after CRT due to preoperative diagnosis of three-vessel coronary
artery disease. A total of 38 patients were included (Fig. 1).
Characteristics of study patients are summarized in Table 1.
2.2. Neoadjuvant CRT
Chemotherapy regimens consisted of either capecitabine or 5-
fluorouracil (5-FU) plus leucovorin, which oncologists decided
based on discussions with patient. Radiation therapy consisted of
a 45-Gy dose delivered to the whole pelvis in 25 fractions,
followed by a 5.4-Gy boost targeting the primary tumor and the
adjacent mesorectum delivered in 3 fractions. Patients receiving
5-FU plus leucovorin were administered two cycles of intrave-
nous bolus injection of 5-FU (425mg/m2/day) and leucovorin
(20mg/m2/day) during the first and fifth weeks of radiation
therapy. Capecitabine patients received 850mg/m2 orally twice
daily throughout radiotherapy. One of these patients was treated
with a reduced dose of capecitabine due to creatinine elevation
during treatment. Patients underwent curative surgery 6 to
10 weeks after the completion of CRT.
2.3. MRI examination
Baseline and post-CRT rectal MRI was performed using a 3.0-T
MR scanner (Magnetom Tim Tio, Siemens Medical Solutions,
Germany; or Ingenia, Philips Medical Systems, the Netherlands)
with a pelvic phased-array surface coil. Intramuscular injection of
20mg scopolamine butylbromide (Buscopan; Boehringer Ingel-
heim Korea, Republic of Korea) was performed 5min before
image acquisition to reduce bowel peristalsis. The scan protocol
of the T2-weighted fast spin-echo sequence is as follows:
repetition time/echo time (ms) 4714 to 6000/110 to 113; matrix
320320mm; section thickness/gap (mm) 3/3. Images were














Age (years) Mean, 60 (range, 34–81)
CRT regimen
5-Fluorouracil with leucovorin 15
Capecitabine 23
Post-CRT surgical method
Total mesorectal excision 36
Local excision 2
Tumor location
Upper rectum (AV>12 cm) 1
Mid-rectum (6cm<AV12 cm) 4





AV= anal verge, CRT= chemoradiation therapy.
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completion of CRT and 2 to 6 weeks before surgery.2.4. Image analysis
Two abdominal radiologists with 6 and 17 years of experience
with rectal MRI, blinded to pathologic results, independently
reviewed baseline and post-CRT MRI and evaluated the
mural extent of the primary tumor as either partial or
transmural (Fig. 2). Based on T2-weighted images of the post-
CRT MRI, two readers assessed mrTRG, as defined by previous
studies[22,23]:1. complete radiologic response (fibrotic scar only);
2. predominantly fibrosis with minimal tumor signal;
3. >50% fibrosis with significant residual tumor;
4. mainly tumor signal;
5. identical appearance to original tumor.
In cases of discrepancy, radiologists verbally discussed
discrepancies to reach a consensus. The 2016 European Society
of Gastrointestinal and Abdominal Radiology (ESGAR) consen-
sus meeting recommended reporting local tumor response after
neoadjuvant CRT in three categories[24]:1. completely normalized rectal wall;
2. fibrotic wall thickening without clear residual mass;
3. residual mass.
Considering the discrepancy between the mrTRG and ESGAR
categories, we defined rCR as either complete normalization of
rectal wall or fibrotic scar only. Corresponding with ESGAR 3,
mrTRG 2 to 4 were categorized as radiologic non-CR (non-rCR).2.5. Pathologic analysis
Pathologic analysis was performed after TME in 36 patients and
local excision in 2 patients. At our hospital, a pathologist
specialized in gastrointestinal pathology for more than 25 years
reported pathologic diagnosis and used the Mandard grades for
pathologic tumor regression grades[25]:3
1. complete regression;
2. fibrosis with scattered tumor cells;
3. fibrosis and tumor cells with a preponderance of fibrosis;
4. fibrosis and tumor cells with a preponderance of tumor cells;
5. tumor without changes of regression.
Based on the surgical pathologic report, Mandard grade 1 was
categorized as pCR and grades 2 to 4 were categorized as non-
pCR in this study; no patients in this study were Mandard grade
5. Final pathologic tumor stages were evaluated based on TNM
system; ypT0, ypTis, and ypT1 cancers were considered early-
stage cancer in this study.2.6. Statistical analysis
Binary logistic regression was used to evaluate whether rCR and
mural extent of the primary tumor predicted pCR and early-stage
cancer. Additionally, the PPV of rCR and partial extent of
primary tumor for pCR and early-stage cancer were calculated
and analyzed using logistic regression in a generalized estimating
equations model. Inter-reader agreement on mrTRG, rCR, and
mural extent of primary tumor was analyzed by calculation of
weighted kappa. Statistical analyses were performed using IBM
SPSS version 24.0 (IBM Corp, Armonk, NY) and MedCalc
(version 13.3, MedCalc Software, Mariakerke, Belgium). A P-
value <.05 was considered statistically significant.3. Results
3.1. Radiologic and pathologic assessment
The distributions ofMandard grade, T stage, and mrTRG among
patients are summarized in Table 2. Out of 38 patients, 68.4%
(26/38) were evaluated as rCR and, among non-rCR patients,
mrTRG 2, 3, and 4 comprised 10.5% (4/38), 13.2% (5/38), and
7.9% (3/38) of patients, respectively. On baseline MRI, the
primary tumor of 21 patients (21/38, 55.3%) involved partial
thickness of the rectal wall and transmural extent of the tumor
was observed in the remaining 17 patients (17/38, 44.7%). After
CRT, the mural extent of the primary tumor decreased from
transmural to partial in seven patients; in all, tumors were limited
to partial extent in 73.7% (28/38) of patients on post-CRTMRI.
Weighted kappas between the two readers were 0.557 for
mrTRG, 0.588 for rCR, 0.694 for mural extent of primary tumor
on baseline MRI, and 0.681 for mural extent of primary tumor
on post-CRTMRI, collectively demonstrating a moderate degree
of inter-reader agreement. According to final pathology reports,
18 patients (18/38, 47.4%) achieved pCR; among non-pCR
patients, the tumors of 13 (13/38, 34.2%), 6 (6/38, 15.8%), and 1
(1/38, 2.6%) patients were Mandard grade 2, 3, and 4,
respectively. Twenty-eight patients (28/38, 73.7%) had early-
stage cancer, and 10 patients (10/38, 26.3%) had ypT2 rectal
cancer. None of the patients were ypT3 or ypT4. Representative
cases of rCR and non-rCR that were confirmed as pCR and non-
pCR, respectively, are depicted in Figure 3.
3.2. Prevalence of pCR and early-stage cancer
Among the 26 patients evaluated as rCR, 16 patients (16/26,
61.5%) achieved pCR and 23 patients (23/26, 88.5%) were
diagnosed with early-stage cancer (Table 3). In patients showing
rCR, the odds ratio (OR) of achieving pCRwas 8.00 (P= .02) and
regression to early-stage cancer was 10.7 (P= .01), both of which
Figure 2. Representative images of the mural extent of primary tumor on baseline (left) and post-chemoradiation (CRT) (right) T2-weighted magnetic resonance
imaging (MRI). The mural extent of the lesion was determined without differentiation between fibrosis and viable tumor signal. (A) Axial images of a 50-year-old
woman showing the partial extent of the primary tumor on baseline MRI, which remained partial in extent on the post-CRT MRI. (B) Axial images of a 65-year-old
man showing the transmural extent of the primary tumor on baseline MRI, which decreased to partial extent on the post-CRT MRI. (C) Axial images of a 75-year old
woman showing the transmural extent of the primary tumor on baseline MRI, which remained transmural in extent on the post-CRT MRI.
Bae et al. Medicine (2020) 99:42 Medicinewere statistically significant results. Among patients with partial
extent of the primary cancer on baselineMRI, 11 patients (11/21,
52.4%) had pCR and 18 patients (18/21, 85.7%) received a
pathologic diagnosis of early-stage cancer (Table 3). Partial
extent of the tumor on baseline MRI did not predict both pCR
(OR=1.6, P= .49) and early-stage cancer (OR=4.2, P= .07).
Out of 28 patients with partial extent of the primary cancer on the
post-CRT MRI, pCR, and early-stage cancer were found in 16
patients (16/28, 57.1%) and 24 patients (24/28, 85.7%),
respectively (Table 3). Partial extent of the tumor on the post-
CRT resulted in greater likelihood of pathologic diagnosis of
early-stage cancer (OR=9.0, P= .01), whereas its impact on the
odds of achieving pCR was statistically insignificant (OR=5.3,
P= .06).4
3.3. PPV of rCR and partial mural extent for pCR and
early-stage cancer
Among 38 patients with clinical T1/T2 rectal cancer included in
this study, 47.4% (18/38) achieved pCR, and early-stage cancer
was achieved in 73.7% (28/38). PPVs of rCR, partial extent of
tumor on baseline MRI, partial extent of tumor on post-CRT
MRI, the combination of rCR with partial extent of tumor on
baseline MRI, and the combination of rCR with partial extent of
tumor on post-CRT MRI are summarized in Table 4. Although
PPVs for pCR under all five conditions were numerically higher
than the observed pCR rate, only rCR and rCR plus partial extent
on the post-CRT MRI showed statistically significantly higher
PPV (61.5%, P= .01; 60.0%, P= .03, respectively). Compared to
observed early stage cancer rate of 73.7%, PPVs for early-stage
Table 2
Distribution of rCR,mural extent of primary tumor,Mandard grade,
and tumor stage.
Parameter Value
rCR (mrTRG 1) 68.4% (26/38)
Non-rCR (mrTRG 2–4)
mrTRG 2 10.5% (4/38)
mrTRG 3 13.2% (5/38)
mrTRG 4 7.9% (3/38)
Mural extent of the tumor on baseline MRI
Partial extent 55.3% (21/38)
Transmural extent 44.7% (17/38)
Mural extent of the tumor on post-CRT MRI
Partial extent 73.7% (28/38)
Transmural extent 26.3% (10/38)
Mandard grade
Grade 1 47.4% (18/38)
Grade 2 34.2% (13/38)
Grade 3 15.8% (6/38)
Grade 4 2.6% (1/38)
Pathologic tumor stage





CRT= chemoradiation therapy, MRI=magnetic resonance imaging, mrTRG=magnetic resonance
imaging tumor regression grade, rCR= radiologic complete response.
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(88.5%, P= .02), partial extent of the tumor (85.7%, P= .03) and
rCR plus partial extent of the tumor (88.0%, P=0.02).4. Discussion
Although organ-preserving strategies can ameliorate morbidity
associated with TME, local tumor recurrence is a major concern.
Therefore, this approach should be carefully applied under
selective conditions in which clinical or imaging criteria
conservatively define patients as candidates under conditions
with maximal PPVs for CR. For patients with cT1/T2 distal rectal
cancer, local excision after CRTmight be an alternative approach
for quality of life. Noh et al reported that CRT before local
excision of cT2 distal rectal cancer decreases the incidence of
local recurrence to 0% in ypT0, 2% in ypT1, and 7% in ypT2.[5]Table 3
Odds ratios of achieving pCR and early-stage cancer.
pCR rate
Odds ratio of ach
pCR (95% CI, P-




Partial/transmural extent of the
tumor on baseline MRI





Partial/transmural extent of the
tumor on post-CRT MRI





CI= confidence interval, CRT= chemoradiation therapy, MRI=magnetic resonance imaging, pCR=path
∗
Early-stage cancer includes pathologic T0, Tis, and T1.
†MRI tumor regression grade (mrTRG) 1 was categorized as rCR, and mrTRG 2, 3, and 4 were catego
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In 59% of their cT2 patients,[5] pCR was obtained, which is
markedly higher than in routine CRT settings for advanced rectal
cancer (15–27%).[1] Therefore, we evaluated whether baseline
and post-CRT MRI carry PPVs for selecting candidates to
meet the conservative conditions necessary to perform organ-
preserving strategies and avoid local recurrence.
In this study, patients with T1/T2 rectal cancer on baseline
MRI were selected, and 47.4% achieved pCR after CRT and
surgical excision, which exceeds the 15% to 27% rate of pCR
reported for advanced rectal cancer.[1] The PPV of rCR for pCR
(61.5%, P= .01) was higher than the study-wide pCR rate
(47.4%). PPV of rCR for early-stage cancer (88.5%, P= .02) was
also higher than observed early stage cancer rate (73.7%). The
PPVs of partial extent of the tumor on both baseline and post-
CRT MRI for pCR and early-stage cancer were not statistically
significantly higher than rCR. Moreover, combining rCR with
mural extent on baseline or post-CRTMRI did not increase PPV
relative to rCR alone.
Our study demonstrated that rCR can be used as a supportive
imaging feature to predict pCR in patients with T1/T2 rectal
cancer. These findings could help clinicians determine whether
radical surgery or less aggressive treatment is more appropriate.
Our study’s results differ from those of a previous study that
indicates a low agreement betweenmrTRG and pathologic tumor
regression, concluding that mrTRG could not replace pathologic
tumor regression.[26] The possible explanation for this disagree-
ment is that more advanced cancer patients were included in that
study than ours, which included only patients with cT1/T2 stage
rectal cancer. Indeed, another study shows that favorable or
unfavorable responses to CRT can be predicted by mrTRG
evaluated on post-CRT MRI.[27]
Some limitations exist in our study. Relatively small number of
patients was included in this study, because standard treatment
for clinical T1/T2 rectal cancer was not neoadjuvant CRT but
surgery. Although we did not assess lymph node metastasis in
post-CRT MRI; future studies should include lymph node
evaluation because patients with lymph node metastasis are not
candidates for local excision or watch-and-wait management.
Finally, diffusion-weighted imaging (DWI) was not included in
this study, although it has recently been used to evaluate the
possibility of pCR after CRT.[28]
In conclusion, rCR on post-CRT MRI can guide management
decisions around organ-saving treatments after CRT in patients
with clinical T1/T2 rectal cancer.ieving
value) Early-stage cancer rate




–44.30, rCR, 88.5% (23/26)
non-rCR, 41.7% (5/12)
10.7 (95% CI=2.04–56.60, P= .01).
–5.71, Partial extent, 85.7% (18/21)
Transmural extent,
58.8% (10/17)
4.2 (95% CI=0.88–19.94, P= .07).
–29.81, Partial extent, 85.7% (24/28)
Transmural extent,
40.0% (4/10)
9.0 (95% CI=1.73–46.84, P= .01).
ologic complete response, rCR= radiologic complete response.
rized as non-rCR.
Table 4
Comparison of PPVs for pCR and early-stage cancer of six different conditions.
PPV for pCR P PPV for early-stage cancer
∗
P
Observed rate (cT1/T2) 47.4% (18/38) 73.7% (28/38)
rCR† 61.5% (16/26) .01 88.5% (23/26) .02
Partial extent on baseline MRI 52.4% (11/21) .49 85.7% (18/21) .07
Partial extent on post-CRT MRI 57.1% (16/28) .05 85.7% (24/28) .03
rCR and partial extent on baseline MRI 52.6% (10/19) .52 84.2% (16/19) .14
rCR and partial extent on post-CRT MRI 60.0% (15/25) .03 88.0% (22/25) .02
CR= complete response, CRT= chemoradiation therapy, MRI=magnetic resonance imaging, pCR=pathologic complete response, PPV=positive predictive value, rCR= radiologic CR.
∗
Early-stage cancer includes pathologic T0, Tis, and T1.
†MRI tumor regression grade (mrTRG) 1 was categorized as rCR, and mrTRG 2, 3, and 4 were categorized as non-rCR.
Figure 3. Representative cases of radiologic complete response (rCR) and radiologic noncomplete response (non-rCR) in T2-weighted magnetic resonance
imaging (MRI). Figures on the left and right are before and after neoadjuvant chemoradiation therapy (CRT), respectively. (A) A 70-year-old man with biopsy-
confirmed rectal cancer in the right lateral wall of themid-rectum. A change to homogenous, low signal intensity was seen post-CRT, whichwas categorized as rCR.
The pathologic report indicated that pathologic complete response (pCR) (Mandard grade 1) was achieved. (B) A 65-year-old woman with biopsy-confirmed rectal
cancer in the lower rectum. Although she was assessed as rCR on the post-CRT MRI, surgical pathology reported pathologic noncomplete response (non-pCR)
(Mandard grade 2 and ypT1). (C) A 36-year-old man with biopsy-confirmed rectal cancer in the posterior wall of the lower rectum, evaluated as non-rCR; the final
pathology report also indicated non-pCR (Mandard grade 3 and ypT3). (D) A 55-year-old woman with biopsy-confirmed rectal cancer in the posterior wall of the
upper rectum was evaluated as non-rCR post-CRT, but the final pathology reported pCR (Mandard grade 1).
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